ArticleActa neuropathologica2012
Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death.
Article in Acta neuropathologica, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- DNA hypermethylation driven by DNMT1 and DNMT3A favors tumor immune escape contributing to the aggressiveness of adrenocortical carcinoma.Clinical epigenetics · 2023Article
- Early ependymal tumor with MN1-BEND2 fusion: a mostly cerebral tumor of female children with a good prognosis that is distinct from classical astroblastoma.Journal of neuro-oncology · 2023Review
- A Proposed Link Between Acute Thymic Involution and Late Adverse Effects of Chemotherapy.Frontiers in immunology · 2022Article
- Review
- Methylation and molecular profiles of ependymoma: Influence of patient age and tumor anatomic location.Molecular and clinical oncology · 2021Article
- Limitations of currentOncotarget · 2018Article
- Region Specific Differences of Claudin-5 Expression in Pediatric Intracranial Ependymomas: Potential Prognostic Role in Supratentorial Cases.Pathology oncology research : POR · 2017Article
- Understanding Ependymoma Oncogenesis: an Update on Recent Molecular Advances and Current Perspectives.Molecular neurobiology · 2017Review
- The Similarities and Differences between Intracranial and Spinal Ependymomas : A Review from a Genetic Research Perspective.Journal of Korean Neurosurgical Society · 2016Review
- Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors.Journal of neuro-oncology · 2016Article
- Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models.Neuro-oncology · 2014Article
- Histologically defined central nervous system primitive neuro-ectodermal tumours (CNS-PNETs) display heterogeneous DNA methylation profiles and show relationships to other paediatric brain tumour types.Acta neuropathologica · 2013Article
- Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system.Brain pathology (Zurich, Switzerland) · 2013Article
- The role of the WNT/β-catenin pathway in central nervous system primitive neuroectodermal tumours (CNS PNETs).British journal of cancer · 2013Article
- Supratentorial ependymoma: disease control, complications, and functional outcomes after irradiation.International journal of radiation oncology, biology, physics · 2013Article
- Emerging insights into the ependymoma epigenome.Brain pathology (Zurich, Switzerland) · 2013Review
- WNT/β-catenin pathway activation in Myc immortalised cerebellar progenitor cells inhibits neuronal differentiation and generates tumours resembling medulloblastoma.British journal of cancer · 2012Article
- PPARG Epigenetic Deregulation and Its Role in Colorectal Tumorigenesis.PPAR research · 2012Article
- Plasma and cerebrospinal fluid pharmacokinetics of the DNA methyltransferase inhibitor, 5-azacytidine, alone and with inulin, in nonhuman primate models.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epigenetic alterations, including methylation, have been shown to be an important mechanism of gene silencing in cancer. Ependymoma has been well characterized at the DNA copy number and mRNA expression levels. However little is known about DNA methylation changes. To gain a more global view of the methylation profile of ependymoma we conducted an array-based analysis. Our data demonstrated tumors to segregate according to their location in the CNS, which was associated with a difference in the global level of methylation. Supratentorial and spinal tumors displayed significantly more hypermethylated genes than posterior fossa tumors, similar to the 'CpG island methylator phenotype' (CIMP) identified in glioma and colon carcinoma. This hypermethylated profile was associated with an increase in expression of genes encoding for proteins involved in methylating DNA, suggesting an underlying mechanism. An integrated analysis of methylation and mRNA expression array data allowed us to identify methylation-induced expression changes. Most notably genes involved in the control of cell growth and death and the immune system were identified, including members of the JNK pathway and PPARG. In conclusion, we have generated a global view of the methylation profile of ependymoma. The data suggests epigenetic silencing of tumor suppressor genes is an important mechanism in the pathogenesis of supratentorial and spinal, but not posterior fossa ependymomas. Hypermethylation correlated with a decrease in expression of a number of tumor suppressor genes and pathways that could be playing an important role in tumor pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.